Melo JV - Search Results

1

RUNX1 mutations are rare in chronic phase polycythaemia vera.

Butcher CM, Neufing PJ, Eriksson L, Carmichael CL, Wilkins EJ, Melo JV, Lewis ID, Bardy PG, Scott HS, D'Andrea RJ. Butcher CM, et al. Among authors: melo jv. Br J Haematol. 2011 Jun;153(5):672-5. doi: 10.1111/j.1365-2141.2011.08589.x. Epub 2011 Feb 20. Br J Haematol. 2011. PMID: 21332713 Free article. No abstract available.

2

Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient.

Rao N, Butcher CM, Lewis ID, Ross DM, Melo JV, Scott HS, Bardy PG, D'Andrea RJ. Rao N, et al. Among authors: melo jv. Br J Haematol. 2012 Jan;156(2):268-70. doi: 10.1111/j.1365-2141.2011.08837.x. Epub 2011 Aug 22. Br J Haematol. 2012. PMID: 21859430 Free article. No abstract available.

3

Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia.

Pabst T, Stillner E, Neuberg D, Nimer S, Willman CL, List AF, Melo JV, Tenen DG, Mueller BU. Pabst T, et al. Among authors: melo jv. Br J Haematol. 2006 May;133(4):400-2. doi: 10.1111/j.1365-2141.2006.06057.x. Br J Haematol. 2006. PMID: 16643447 Free article.

4

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.

Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D'Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP. Hiwase DK, et al. Among authors: melo jv. Leukemia. 2010 Apr;24(4):771-8. doi: 10.1038/leu.2009.299. Epub 2010 Feb 4. Leukemia. 2010. PMID: 20130598

5

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.

Roy S, Jørgensen HG, Roy P, Abed El Baky M, Melo JV, Strathdee G, Holyoake TL, Bartholomew C. Roy S, et al. Among authors: melo jv. Br J Haematol. 2012 May;157(4):446-56. doi: 10.1111/j.1365-2141.2012.09078.x. Epub 2012 Feb 29. Br J Haematol. 2012. PMID: 22372463 Free article.

6

Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia.

Melo JV, Hochhaus A, Yan XH, Goldman JM. Melo JV, et al. Br J Haematol. 1996 Mar;92(3):684-6. doi: 10.1046/j.1365-2141.1996.00350.x. Br J Haematol. 1996. PMID: 8616036

7

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

Barthe C, Gharbi MJ, Lagarde V, Chollet C, Cony-Makhoul P, Reiffers J, Goldman JM, Melo JV, Mahon FX. Barthe C, et al. Among authors: melo jv. Br J Haematol. 2002 Oct;119(1):109-11. doi: 10.1046/j.1365-2141.2002.03708.x. Br J Haematol. 2002. PMID: 12358910 Free article.

8

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.

Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL. Hiwase DK, et al. Clin Cancer Res. 2008 Jun 15;14(12):3881-8. doi: 10.1158/1078-0432.CCR-07-5095. Clin Cancer Res. 2008. PMID: 18559609 Free article.

9

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

Branford S, Melo JV, Hughes TP. Branford S, et al. Among authors: melo jv. Blood. 2009 Dec 24;114(27):5426-35. doi: 10.1182/blood-2009-08-215939. Epub 2009 Oct 30. Blood. 2009. PMID: 19880502 Free article.

10

Do we have to kill the last CML cell?

Ross DM, Hughes TP, Melo JV. Ross DM, et al. Among authors: melo jv. Leukemia. 2011 Feb;25(2):193-200. doi: 10.1038/leu.2010.197. Epub 2010 Sep 16. Leukemia. 2011. PMID: 20844563 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

227 results

Search Page

Filters